Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma

The VanEck Biotech ETF and State Street SPDR S&P Pharmaceuticals ETF both carry an identical expense ratio of 0.35%. The State Street SPDR S&P Pharmaceuticals ETF is more diversified with 62 holdings, while the VanEck Biotech ETF focuses on 25 holdings.

The Motley Fool • Oct 10, 2026

Better Pharma ETF: iShares IHE vs. State Street XPH

The iShares U.S. Pharmaceuticals ETF is significantly more concentrated than the State Street SPDR S&P Pharmaceuticals ETF, with Eli Lilly accounting for 23.63% of the portfolio. The iShares U.S. Pharmaceuticals ETF provides a higher dividend yield of 1.4% compared to 0.4% for the State Street SPDR S&P Pharmaceuticals ETF.

The Motley Fool • Oct 10, 2026

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on June 19, 2006.

Zacks Investment Research • Oct 8, 2026

Execution of Pharma Tariffs Brings These ETFs Into Focus

Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.

Zacks Investment Research • Oct 6, 2026

IXJ vs XPH: Global Healthcare ETF or Pharma Focus?

iShares Global Healthcare ETF provides broad sector coverage with a higher dividend yield than State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF has delivered stronger total returns over the last year but experiences significantly higher maximum drawdowns.

The Motley Fool • Sep 12, 2026

Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?

Fidelity MSCI Health Care Index ETF offers a lower expense ratio of 0.08% compared to the 0.35% charged by State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF focuses specifically on the pharmaceutical industry, whereas Fidelity MSCI Health Care Index ETF tracks the broader healthcare sector.

The Motley Fool • Sep 10, 2026

Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH

The Vanguard Health Care ETF offers a significantly lower expense ratio and a higher dividend yield than the State Street SPDR S&P Pharmaceuticals ETF. The State Street SPDR S&P Pharmaceuticals ETF provides concentrated exposure to drug manufacturers, while the Vanguard Health Care ETF covers a broader range of medical services and equipment.

The Motley Fool • Sep 10, 2026

Ditch These Historic ETF September Underperformers

Subscribers to  Chart of the Week  received this commentary on Sunday, Sept.

Schaeffers Research • Sep 8, 2026

XPH vs PJP: Which Pharma ETF Offers Better Value

The State Street SPDR S&P Pharmaceuticals ETF offers a significantly lower expense ratio of 0.35% compared to the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF provides a more concentrated portfolio of 29 stocks and lower price volatility as measured by beta.

The Motley Fool • Aug 17, 2026

Better Healthcare ETF: State Street's Pharmaceuticals-Focused XPH vs. Invesco's S&P 500-Targeted RSPH

The Invesco S&P 500 Equal Weight Health Care ETF provides broad exposure to the sector, while the State Street SPDR S&P Pharmaceuticals ETF focuses specifically on the pharmaceutical industry. The State Street SPDR S&P Pharmaceuticals ETF has significantly outperformed over the last year, though it carries higher concentration risk and historical volatility.

The Motley Fool • Aug 12, 2026